Why the study?
Patients with T2DM face elevated coronary atherosclerosis risk and CYP2C19 is linked to cardiovascular disease, prompting investigation of CYP2C19 polymorphisms and coronary atherosclerosis risk in T2DM.
Does CYP2C19 intermediate or poor metabolizer status increase the risk of coronary atherosclerosis in patients with type 2 diabetes mellitus?
Does CYP2C19 intermediate or poor metabolizer status increase the risk of coronary atherosclerosis in patients with type 2 diabetes mellitus?
CYP2C19 intermediate and poor metabolizer phenotypes are independently associated with an increased risk of coronary atherosclerosis in patients with type 2 diabetes mellitus.
Should not yet change practice; leaves open a causal role for CYP2C19 IM/PM in T2DM coronary atherosclerosis.
Type 2 diabetes mellitus (T2DM) has a higher risk of coronary atherosclerosis (CAS) compared to the general population. Cytochrome P450 2C19 (CYP2C19) closely related to the occurrence and development of cardiovascular diseases. This study intends to conduct research on the relationship between CYP2C19 polymorphisms ((rs4244285, 681G > A, *2) and (rs4986893, 636G > A, *3)) and the risk of CAS in patients with T2DM. 4,627 T2DM patients from January 2019 to March 2024 were retrospectively analyzed, included 2,390 cases of T2DM complicated with CAS and 2,237 cases of patients with T2DM only. CYP2C19 was divided into three phenotypes: extensive metabolizer (EM), intermediate metabolizer (IM), and poor metabolizer (PM) based on rs4244285 and rs4986893 SNPs. The relationship between CYP2C19 polymorphisms and CAS risk was analyzed. There were 1,403(30.3%) patients with dyslipidemia, and dyslipidemia (41.1% vs. 18.8%, p < 0.001) in patients with CAS was higher than those in controls. The frequencies of CYP2C19 IM and PM phenotypes in CAS patients were higher than those in controls. Logistic regression analysis showed that advanced age (odds ratio (OR): 1.273, 95% confidence interval (CI): 1.099–1.473, p = 0.001), overweight (OR: 1.175, 95% CI: 1.039–1.328, p = 0.010), smoking (OR: 1.238, 95% CI: 1.049–1.462, p = 0.012), alcoholism (OR: 1.445, 95% CI: 1.040–2.007, p = 0.028), hypertension (OR: 1.229, 95% CI: 1.047–1.442, p = 0.012), dyslipidemia (OR: 3.027, 95% CI: 2.641–3.469, p < 0.001), CYP2C19 IM/PM phenotype(IM + PM vs. EM phenotype, OR: 1.290, 95% CI: 1.140–1.459, p < 0.001) were associated with CAS in T2DM. CYP2C19 IM + PM phenotypes, advanced age, overweight, history of smoking, history of alcoholism, hypertension, and dyslipidemia may be associated with CAS in T2DM.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: